Monopar Therapeutics
MNPR
4 hedge funds and large institutions have $439K invested in Monopar Therapeutics in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.06% more ownership
Funds ownership: 0% → 0.06% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$272K |
| 2 |
Morgan Stanley
New York
|
+$222K |
| 3 |
PCM
Prelude Capital Management
New York
|
+$31.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$26.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of Montreal
Toronto,
Ontario, Canada
| $216K | +$272K | +2,600 | New |
|
|
2
Morgan Stanley
New York
| $177K | +$222K | +2,126 | New |
|
|
PCM
3
Prelude Capital Management
New York
| $25K | +$31.5K | +302 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $21K | +$26.9K | +258 | New |
|
MNPR Hedge Fund Activity: Q4 2019 in Review
4 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2019, worth a combined $439K.
Buyers outnumbered sellers: 4 funds opened new MNPR positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $272K.
- 4 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $439K of Monopar Therapeutics stock for Q4 2019.
- 4 funds opened new Monopar Therapeutics positions in Q4 2019 and 0 closed out, a net change of +4 holders.
- The largest Monopar Therapeutics buyer in Q4 2019 was Bank of Montreal, an estimated $272K added.
Based on aggregated 13F filings for Q4 2019.